Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial

作者：Zikun Peng, Huayi Li, Yunong Gao, Li Sun, Jie Jiang, Bairong Xia, Yi Huang, Yu Zhang, Yu Xia, Yuxin Zhang, Yiyang Shen, Bowen Huang, Jiayu Nie, Xinrong Chen, Xingyu Liu, Feng Cui, Zhen Li, Wei Zhang, Kangjia Tao, Qiuxue Zhang, Shican Duan, Yaheng Chen, Yeshan Chen, Wei Wang, Hong Zheng, Yudong Lu, Yi Liu, L. Wang, Wen-Cai Qi, Yang He, Yan Tian, Ting Hu, Shaoqing Zeng, Ya Wang, Jianhua Chi, Xiaofei Jiao, Jiahao Liu, Ming Li, Yuanjia Wen, Fan Xiong, Yu Xu, Guanchen Ma, Yingjun Zhao, Yang Yu, Ruyuan Li, Guiling Li, Ding Ma, Qinglei Gao · 发表于：The Lancet Oncology · 年份：2024 · DOI：10.1016/s1470-2045(24)00437-6 · 被引用次数：31 · 研究领域：Ovarian cancer diagnosis and treatment、PARP inhibition in cancer therapy、Chromatin Remodeling and Cancer